“Imagine that every time you were doing IND-enabling studies, you could also run a lifespan study in mice,” said the paper’s lead author, Insilico CEO Alex Zhavaronkov. “Every pharma program hits the 12-month IND-enabling window. Why not use that same year to run a parallel mouse lifespan study?”
2 Likes
The only problem is cost.
However, I love the idea.
2 Likes
Wouldn’t be that expensive compared to what companies spend. It would also be very good data.
1 Like
Having for decades observed how frequently studies on mice fail to generalize to humans, I’m on the other side of this issue. ITP, for example, is a worthwhile but overinterpreted initiative.
1 Like
2 Likes
Ok so it’s basically happening. Even better. Slight alterations to these types of tests can make them suitable for lifespan analysis.